Work

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study

Year: 2018

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-17-2822

Authors: Daniel J. George, Jean-François Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, Sherry Li, Michelle Casey, Brigitte Laguerre, Hardev S. Pandha, Allan J. Pantuck, Anup Patel, Maria J. Lechuga, Alain Ravaud

Institutions: Duke Cancer Institute, München Klinik, Memorial Sloan Kettering Cancer Center, Charité – Universitätsmedizin Berlin, Institut Gustave Roussy, Pfizer (United States), Centre Eugène Marquis, University of Surrey, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Spire London East Hospital, Centre Hospitalier Universitaire de Bordeaux

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

Award: G6516949535

OpenAlex ID: W2789398755

FWCI: 4.521

Cites: 25

Cited by: 37

Related to: 10